NCT04260113View on ClinicalTrials.gov

Apatinib for Inoperable Advanced Chondrosarcoma

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

January 1, 2020

Study Completion Date

April 1, 2020

Conditions
EfficacyToxicity, Drug
Interventions
DRUG

Apatinib Mesylate

Apatinib orally 500mg once daily half an hour after meal

Trial Locations (2)

100044

Musculoskeletal Tumor Center of Peking University People's Hospital, Beijing

100144

Peking Univresity Shougang Hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER

NCT04260113 - Apatinib for Inoperable Advanced Chondrosarcoma | Biotech Hunter | Biotech Hunter